Table 1.
Currently published case reports of CML developing after solid organ transplantation.
| Reference | Age (years) | Sex | Immunosuppression | Latency (mo) | Best response to TKI | Time to best response (mo) | WBC/μL | Comment |
|---|---|---|---|---|---|---|---|---|
| Cases of kidney transplantation | ||||||||
| Battin et al., 1976 [4] | 15 | m | A | 48 | — | — | — | |
| Adler et al., 1978 [5] | 18 | m | A, S, R | 32 | — | — | — | |
| Lubynski et al., 1978 [6] | 20 | m | A, S | 35 | — | — | 69.000 | |
| Mooy et al., 1978 [7] | 40 | m | A, S, Actinomycin C | 48 | — | — | — | |
| Hilario et al., 1980 [8] | 26 | f | A, S | 60 | — | — | — | |
| Kirchner et al., 1983 [9] | 31 | f | A, S, R | 42 | — | — | 73.000 | Retransplantation |
| Sanz et al., 1996 [11] | 59 | m | A | 72 | — | — | — | |
| Stein et al., 1978 [12] | 19 | m | A, S | 18 | — | — | — | |
| Mignozzi and Picca, 2001 [13] | 16 | m | A, OKT-3, C, S | 96 | — | — | 65.000 | |
| Pescovitz et al., 1996 [14] | 52 | m | A, ALG, S, C | 0 | — | — | 14.700 | |
| Penn, 1998 [15] | Child | — | A, OKT-3 | — | — | — | — | |
| Pelloso et al., 2005 [16] | 37 | m | A, C, S | 30 | — | — | 92.000 | |
| Koca et al., 2005 [17] | 33 | m | A, S, C | 87 | Imatinib/CCyR | — | — | |
| Thierry et al., 2007 [19] | 53 | f | ATG, C, M, S | 25 | Imatinib/MR4 | 8 | 28.600 | |
| Fontana et al., 2008 [20] | 54 | f | T, S, M | 63 | Imatinib/CHR | 2 | 87.540 | |
| le Coutre et al., 2010 [21] | 39 | m | T, C | 38 | Imatinib/NA | NA | 41.300 | |
| le Coutre et al., 2010 [21] | 47 | f | T, C, S | 183 | Nilotinib/CCyR | NA | 27.700 | Retransplantation |
| le Coutre et al., 2010 [21] | 54 | f | C, M, S | 11 | NA | NA | 139.000 | |
| Castillo-Rama et al., 2009 [22] | 48 | m | A, S, C, M | 204 | Imatinib/MR4 | 60 | 34.500 | Retransplantation |
| Sayar et al., 2011 [23] | 18 | m | ATG, S, M, T | 13 | Imatinib/HR | 0,5 | 37.000 | |
| Sayar et al., 2011 [23] | 56 | m | ATG, S, M, T | 10 | Imatinib/HR | NA | 39.000 | |
| Oskuei et al., 2014 [25] | 63 | m | C, M, S | 26 | Imatinib/CHR | 2 | 59.000 | |
| Dhanarajan et al., 2014 [26] | 59 | m | Sirolimus | 120 | Imatinib/CCyR | 6 | NA | |
| Dhanarajan et al., 2014 [26] | 77 | f | S, T, M | 12 | Imatinib/HR | 1 | NA | |
| Dhanarajan et al., 2014 [26] | 48 | f | S, T | 72 | Imatinib/CCyR | 6 | NA | Combined kidney pancreas transplantation |
| Cases of liver transplantation | ||||||||
| Fontana et al., 2008 [20] | 55 | m | T, S | 64 | Imatinib/CHR | 3 | 6.200 | |
| Fontana et al., 2008 [20] | 59 | f | T, S | ca. 18 | Imatinib/CHR | 6 | 84.600 | |
| le Coutre et al., 2010 [21] | 63 | m | T | 32 | Imatinib/CCyR | 4 | 37.700 | |
| Dhanarajan et al., 2014 [26] | 52 | m | S, T | 48 | Imatinib/MR4 | 18 | NA | |
| Cases of lung transplantation | ||||||||
| Dhanarajan et al., 2014 [26] | 50 | m | S, T, A | 18 | Imatinib/MR4 | 22 | NA | |
| Cases of heart transplantation | ||||||||
| Frist and Biggs. 1994 [10] | 31 | m | A, C, OKT-3, S, R | 84 | — | — | — | Retransplantation |
| Sbenghe et al., 2011 [24] | 54 | m | T, M | 14 | Imatinib/NA | NA | 68.000 | |
| Menon et al., 2014 [27] | 4 | f | T, M | 9 | Dasatinib/NA | NA | 77.700 | Secondary CML after AML |
| Present case | 63 | m | C, M, S | 16 | Imatinib/CCyR | 15 | 33.000 |
A, azathioprine; C, cyclosporine A; S, steroids; ATG/ALG, antithymocyte globulin/antilymphocyte globulin; M, mycophenolate mofetil; T, tacrolimus; R, radiation; NA, not available; WBC: white blood cell count at diagnosis. Retransplantation: several transplantations of the same organ were performed sequentially. Modified according to le Coutre et al. [21].